Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for Leora Horn

11 Open Trials

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCTHO1718

    08/17/2017

    Randomized, Open-Label, Phase 3 Trial of Nivolumab and Ipilimumab versus Platinum-Doublet Chemotherapy in Early Stage NSCLC (CheckMate 816: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 816)

    Treatment

    VICCTHO1684

    07/20/2017

    Phase I Trial of Combination Afatinib and Necitumumab in EGFR Mutation Positive NSCLC with Acquired Resistance to First or Third Generation EGFR TKIs

    Treatment

    VICCTHO16139

    06/13/2017

    A Parallel Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1722

    05/26/2017

    Phase I Study of TRC102 in Combination with Cisplatin and Pemetrexed in Patients with Advanced Solid Tumors, with Expansion Cohort in Mesothelioma / Phase II Study of TRC102 with Pemetrexed in Patients Refractory to Pemetrexed and Cisplatin or Carboplatin

    Treatment

    VICCTHO16148

    05/25/2017

    A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1691

    04/25/2017

    A Phase II Single-Arm Trial to Investigate Tepotinib in advanced (Stage IIIB/IV) Non-Small Cell Lung Cancer with MET Exon 14 (METex14) Skipping Alterations After Failure of at Least One Prior Active Therapy, Including a Platinum-Doublet-Containing Regimen

    Treatment

    VICCTHO1614

    08/05/2016

    A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor AP32788 in Non-Small Cell Lung Cancer

    Treatment

    VICCTHO15129

    06/07/2016

    XALT3: Phase 3 Randomized Study Comparing X-396 to Crizotinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients

    Treatment

    VICCTHO1510

    07/09/2015

    A Phase 2 Study of MM-121 in Combination with Docetaxel or Pemetrexed versus Docetaxel or Pemetrexed Alone in Patients with Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Treatment

    VICCTHO1478

    11/14/2014

    A Multi-arm, Phase Ib, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Combination with Ascending Doses of Novel Therapeutics in Patients with EGFRm+ Advanced NSCLC who have progressed following therapy with an EGFR TKI (TATTON)

    Treatment

    VICCTHN1244

    07/25/2012

    Phase I/II, First-in-Human, Dose-Escalation Study of X-396 in Patients with Advanced Solid Tumors and Expansion Phase in Patients with ALK+ Non-Small Cell Lung Cancer


    Print this page for your doctor